Literature DB >> 19526584

Impulsive and compulsive behaviors in Parkinson's disease.

Andrew H Evans1, Antonio P Strafella, Daniel Weintraub, Mark Stacy.   

Abstract

Antiparkinson therapy can be the primary cause of a range of nonmotor symptoms that include a set of complex disinhibitory psychomotor pathologies and are linked by their repetitive, reward or incentive-based natures. These behaviors relate to aberrant or excessive dopamine receptor stimulation and encompass impulse control disorders (ICDs), punding, and the dopamine dysregulation syndrome (DDS). Common ICDs include pathological gambling, hypersexuality, compulsive eating, and compulsive buying. This review focuses on the phenomenology, epidemiology, and methods to identify and rate these disorders. The management of dopaminergic drug-related compulsive behaviors is discussed in the light of the current understanding of the neurobiological substrate of these disorders. 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19526584     DOI: 10.1002/mds.22505

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  59 in total

1.  PINK1: pumps, paraesthesia, punding and psychosis.

Authors:  Dominic C Paviour; Marie-Helene Marion
Journal:  J Neurol       Date:  2011-11-30       Impact factor: 4.849

2.  Zonisamide in managing impulse control disorders in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Cristina Ruiz-Huete; Buenaventura Anciones
Journal:  J Neurol       Date:  2010-05-28       Impact factor: 4.849

3.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 4.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

5.  Betting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's disease.

Authors:  Jason Brandt; Mark Rogerson; Haya Al-Joudi; Gila Reckess; Barnett Shpritz; Chizoba C Umeh; Noha Aljehani; Kelly Mills; Zoltan Mari
Journal:  Neuropsychology       Date:  2014-12-08       Impact factor: 3.295

6.  Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.

Authors:  Jesús Pérez-Pérez; Javier Pagonabarraga; Saül Martínez-Horta; Ramón Fernández-Bobadilla; Salvador Sierra; Berta Pascual-Sedano; Alexandre Gironell; Jaime Kulisevsky
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

7.  Hypomania and saccadic changes in Parkinson's disease: influence of D2 and D3 dopaminergic signalling.

Authors:  Esther A Pelzer; Barbara Dillenburger; Sophie Grundmann; Vladimir Iliaev; Sophie Aschenberg; Corina Melzer; Martin Hess; Gereon R Fink; Carsten Eggers; Marc Tittgemeyer; Lars Timmermann
Journal:  NPJ Parkinsons Dis       Date:  2020-01-17

8.  A case of sleep masturbation related to dopamine agonist therapy.

Authors:  Robert J Sawyer; Randy A Sansone
Journal:  Prim Care Companion CNS Disord       Date:  2012-05-10

9.  Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions?

Authors:  Atbin Djamshidian; Sean S O'Sullivan; Yanosh Sanotsky; Stephen Sharman; Yuriy Matviyenko; Thomas Foltynie; Rosanna Michalczuk; Iciar Aviles-Olmos; Ludmyla Fedoryshyn; Karen M Doherty; Yuriy Filts; Marianna Selikhova; Henrietta Bowden-Jones; Eileen Joyce; Andrew J Lees; Bruno B Averbeck
Journal:  Mov Disord       Date:  2012-07-20       Impact factor: 10.338

Review 10.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.